JP2021521777A5 - - Google Patents
Info
- Publication number
- JP2021521777A5 JP2021521777A5 JP2020556877A JP2020556877A JP2021521777A5 JP 2021521777 A5 JP2021521777 A5 JP 2021521777A5 JP 2020556877 A JP2020556877 A JP 2020556877A JP 2020556877 A JP2020556877 A JP 2020556877A JP 2021521777 A5 JP2021521777 A5 JP 2021521777A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- enzyme
- transgenic
- cells
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658261P | 2018-04-16 | 2018-04-16 | |
| US62/658,261 | 2018-04-16 | ||
| PCT/US2019/027623 WO2019204269A1 (en) | 2018-04-16 | 2019-04-16 | Human kynureninase enzymes and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521777A JP2021521777A (ja) | 2021-08-30 |
| JP2021521777A5 true JP2021521777A5 (enExample) | 2022-04-07 |
| JP7432851B2 JP7432851B2 (ja) | 2024-02-19 |
Family
ID=68240288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556877A Active JP7432851B2 (ja) | 2018-04-16 | 2019-04-16 | ヒトキヌレニナーゼ酵素及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11648272B2 (enExample) |
| EP (1) | EP3781179A4 (enExample) |
| JP (1) | JP7432851B2 (enExample) |
| KR (1) | KR102862473B1 (enExample) |
| CN (1) | CN112218644A (enExample) |
| AR (1) | AR115051A1 (enExample) |
| AU (1) | AU2019257340B2 (enExample) |
| BR (1) | BR112020020772A2 (enExample) |
| CA (1) | CA3096549A1 (enExample) |
| CL (1) | CL2020002650A1 (enExample) |
| CO (1) | CO2020013050A2 (enExample) |
| EA (1) | EA202092487A1 (enExample) |
| IL (1) | IL277765B1 (enExample) |
| MX (1) | MX2020010932A (enExample) |
| SG (1) | SG11202009559RA (enExample) |
| TW (1) | TWI827593B (enExample) |
| WO (1) | WO2019204269A1 (enExample) |
| ZA (1) | ZA202006077B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102271498B1 (ko) | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| EP3186371B1 (en) * | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3423483B1 (en) | 2016-03-02 | 2025-09-24 | Board Of Regents Of the University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| CN114828863A (zh) * | 2019-10-17 | 2022-07-29 | 医肯纳肿瘤学公司 | 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途 |
| WO2024085280A1 (ko) * | 2022-10-20 | 2024-04-25 | 서울대학교 산학협력단 | 신규한 키뉴레니나제 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194721A1 (en) | 2001-09-19 | 2003-10-16 | Incyte Genomics, Inc. | Genes expressed in treated foam cells |
| JP2005516605A (ja) | 2002-02-01 | 2005-06-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 心血管疾患を処置するための方法および組成物 |
| CN1330774C (zh) | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| US7714139B2 (en) | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| JP2008237022A (ja) | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CA2776143A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| KR20120085209A (ko) | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| US9593062B2 (en) | 2011-09-07 | 2017-03-14 | Deutschland Krebsforschungszentrum | Means and methods for treating and/or preventing natural AHR ligand-dependent cancer |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| KR102271498B1 (ko) | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| EP3186371B1 (en) * | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3423483B1 (en) | 2016-03-02 | 2025-09-24 | Board Of Regents Of the University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
-
2019
- 2019-04-16 BR BR112020020772-1A patent/BR112020020772A2/pt unknown
- 2019-04-16 CA CA3096549A patent/CA3096549A1/en active Pending
- 2019-04-16 US US16/385,562 patent/US11648272B2/en active Active
- 2019-04-16 JP JP2020556877A patent/JP7432851B2/ja active Active
- 2019-04-16 AU AU2019257340A patent/AU2019257340B2/en active Active
- 2019-04-16 EA EA202092487A patent/EA202092487A1/ru unknown
- 2019-04-16 KR KR1020207032702A patent/KR102862473B1/ko active Active
- 2019-04-16 TW TW108113281A patent/TWI827593B/zh active
- 2019-04-16 WO PCT/US2019/027623 patent/WO2019204269A1/en not_active Ceased
- 2019-04-16 EP EP19789290.4A patent/EP3781179A4/en active Pending
- 2019-04-16 CN CN201980025530.2A patent/CN112218644A/zh active Pending
- 2019-04-16 AR ARP190101000A patent/AR115051A1/es unknown
- 2019-04-16 SG SG11202009559RA patent/SG11202009559RA/en unknown
- 2019-04-16 MX MX2020010932A patent/MX2020010932A/es unknown
-
2020
- 2020-09-30 ZA ZA2020/06077A patent/ZA202006077B/en unknown
- 2020-10-03 IL IL277765A patent/IL277765B1/en unknown
- 2020-10-14 CL CL2020002650A patent/CL2020002650A1/es unknown
- 2020-10-19 CO CONC2020/0013050A patent/CO2020013050A2/es unknown
-
2023
- 2023-04-06 US US18/296,687 patent/US12144828B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521777A5 (enExample) | ||
| JP6484634B2 (ja) | Ｉｌ−１５ヘテロ二量体タンパク質及びその用途 | |
| JP2016533753A5 (enExample) | ||
| EP3992210A1 (en) | Novel vaccines against hpv and hpv-related diseases | |
| BR112019013215A2 (pt) | vírus oncolítico, composição farmacêutica, produto de fabricação, método para tratar câncer e uso | |
| WO2018079740A1 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| WO2024119769A9 (zh) | 增强向肿瘤部位浸润能力的car-nk细胞制备及应用 | |
| US11472862B2 (en) | IL13Rα2 peptide and its uses | |
| US12551568B2 (en) | Anti-claudin 6 antibody and antibody-drug conjugate | |
| JP2022518628A (ja) | Ｃｃｌ２１をコードする組換えラブドウイルス | |
| JP2021521777A (ja) | ヒトキヌレニナーゼ酵素及びその使用 | |
| WO2022015711A1 (en) | Fusion proteins of anti-pd-l1 and attenuated interferon, and compositions and therapeutic methods thereof | |
| CN118047878A (zh) | 促进巨噬细胞吞噬的嵌合抗原受体及其制备方法和应用 | |
| CN112996909A (zh) | 表达pd-1结合蛋白的溶瘤病毒及其应用 | |
| JP2023509516A5 (enExample) | ||
| JP2025515206A (ja) | Ｕｔｒを含む核酸構築物及びその使用 | |
| WO2024113715A1 (zh) | 制备沉默nkg2a基因的nk细胞的方法及其用途 | |
| CN111118063B (zh) | 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用 | |
| CN108815188A (zh) | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 | |
| JP7774268B2 (ja) | 組換え霊芝免疫調節タンパク質の新規変異体及びその応用 | |
| CN114712393A (zh) | Hnf-1α基因修饰的间充质干细胞在防治肝癌中的用途 | |
| CN116724110A (zh) | 重组溶瘤病毒及其构建方法和用途 | |
| BR112020022062A2 (pt) | usos médicos | |
| CN116270990B (zh) | Adam17在制备治疗效应性cd8+t细胞分化相关疾病药物中的用途 | |
| CN114903989B (zh) | 干细胞细胞因子联合螺旋藻多糖制备的药物或化妆品 |